A Phase 3 interventional study of Gadoterate meglumine (Dotarem) and Time of Flight Magnetic Resonance Angiography in Renal Artery Stenosis, sponsored by Guerbet. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.
Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 3, and was the 9th registered.
59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.
Browse Renal Artery Obstruction studies →None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →
Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 1992; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 42 interventional studies indexed under Renal Artery Obstruction.
Median enrollment 64 across the 14 interventional studies, 75 across the 1 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 1 study filed under Renal Artery Obstruction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Renal Artery Obstruction with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject will receive one injection of Dotarem 0.2 ml/kg.
Drug: Gadoterate meglumine (Dotarem)
Each subject undergo a TOF MRA
Other: Time of Flight Magnetic Resonance Angiography
Each subject will receive one injection of Dotarem 0.2 ml/kg
Each subject will undergo a TOF MRA
Percent of Non Assessable Renal Artery Segments
For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared
Time frame: 1 to 7 days
First Patient First Visit: Apr 2009 Last Patient Last Visit: Feb 2010 Location: Radiology centers
| Milestone | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Started | 33 |
| Completed | 32 |
| Not completed | 1 |
| Milestone | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Started | 32 |
| Completed | 32 |
| Not completed | 0 |
For each examination (TOF and Dotarem MRA) the percent of non-assessable segment will be compared
No measurements were reported for this outcome.
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem Magnetic Resonance Angiography | — | 1/32 (3.1%) | 6/32 (18.8%) |
| Time Of Flight MRA | — | 0/32 (0%) | 0/32 (0%) |
| Event | Dotarem Magnetic Resonance Angiography | Time Of Flight MRA |
|---|---|---|
| Mental status changedPsychiatric disorders | 1/32 | 0/32 |
| Event | Dotarem Magnetic Resonance Angiography | Time Of Flight MRA |
|---|---|---|
| InvestigationInvestigations | 3/32 | 0/32 |
| General disordersGeneral disorders | 2/32 | 0/32 |
| InfectionInfections and infestations | 1/32 | 0/32 |
Baseline measures were recorded for all 33 patients.
| Age, Categorical(Participants) | TOF and Dotarem Enhanced MRA |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 17 |
| >=65 years | 16 |
| Age, Continuous(years) | TOF and Dotarem Enhanced MRA |
|---|---|
| Mean | 62 ± 15 |
| Sex: Female, Male(Participants) | TOF and Dotarem Enhanced MRA |
|---|---|
| Female | 16 |
| Male | 17 |
| Region of Enrollment(participants) | TOF and Dotarem Enhanced MRA |
|---|---|
| United States | 33 |
The record gives a start of Apr 2009, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine